Your Article Summary
Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine
BioVail Corporation, 06/23/09
Biovail Corporation announced that a wholly owned subsidiary has completed the acquisition of the worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman, and the associated intellectual property rights held by Cambridge Laboratories Limited and its affiliates.
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Tricare contracts may be re-bid after losing plans protest
American Medical News , 11/25/09
GSK Regulatory Update: Avodart
GlaxoSmithKline, 11/24/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Article Search
Sponsor


See Latest Articles


